MX2021006032A - Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la señalización aberrante del interferón gamma. - Google Patents

Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la señalización aberrante del interferón gamma.

Info

Publication number
MX2021006032A
MX2021006032A MX2021006032A MX2021006032A MX2021006032A MX 2021006032 A MX2021006032 A MX 2021006032A MX 2021006032 A MX2021006032 A MX 2021006032A MX 2021006032 A MX2021006032 A MX 2021006032A MX 2021006032 A MX2021006032 A MX 2021006032A
Authority
MX
Mexico
Prior art keywords
steriods
lupus erythematosus
systemic lupus
novel
overcoming resistance
Prior art date
Application number
MX2021006032A
Other languages
English (en)
Spanish (es)
Inventor
Vladimir Evgenievich Nebolsin
Original Assignee
Chemimmune Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemimmune Therapeutics Llc filed Critical Chemimmune Therapeutics Llc
Publication of MX2021006032A publication Critical patent/MX2021006032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021006032A 2018-11-23 2019-11-22 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la señalización aberrante del interferón gamma. MX2021006032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2018141291A RU2712281C1 (ru) 2018-11-23 2018-11-23 Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма
PCT/RU2019/050225 WO2020106191A1 (ru) 2018-11-23 2019-11-22 Производное глутаримида для преодоления резистентности к стероидам

Publications (1)

Publication Number Publication Date
MX2021006032A true MX2021006032A (es) 2021-07-06

Family

ID=69624712

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021006032A MX2021006032A (es) 2018-11-23 2019-11-22 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la señalización aberrante del interferón gamma.
MX2022013503A MX2022013503A (es) 2018-11-23 2021-05-21 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la se?alizacion aberrante del interferon gamma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022013503A MX2022013503A (es) 2018-11-23 2021-05-21 Uso de derivado de glutarimida para superar la resistencia a esteroides y tratar enfermedades relacionadas con la se?alizacion aberrante del interferon gamma.

Country Status (19)

Country Link
US (1) US20220362230A1 (enExample)
EP (2) EP3884945A4 (enExample)
JP (2) JP2022508167A (enExample)
KR (2) KR20220162821A (enExample)
CN (2) CN113164464A (enExample)
AU (2) AU2019384626A1 (enExample)
BR (1) BR112021009801A2 (enExample)
CA (1) CA3120882A1 (enExample)
CL (2) CL2021001316A1 (enExample)
EA (1) EA201992646A1 (enExample)
GE (4) GEAP202215712A (enExample)
IL (2) IL297533A (enExample)
MD (2) MD4851C1 (enExample)
MX (2) MX2021006032A (enExample)
MY (1) MY209416A (enExample)
PH (1) PH12021551152A1 (enExample)
RU (1) RU2712281C1 (enExample)
WO (1) WO2020106191A1 (enExample)
ZA (2) ZA202104247B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (ru) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями
WO2023191666A1 (ru) * 2022-03-29 2023-10-05 Общество С Ограниченной Ответственностью "Валента-Интеллект" Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9111874U1 (de) * 1991-09-23 1991-11-21 Haag, Richard, 7181 Satteldorf Halterung zur Aufnahme und Befestigung von Akkus am Heckbrett in Booten
EP0625045A4 (en) * 1992-02-07 1995-01-18 Albert M Kligman METHOD FOR TREATING FLAMMABLE DERMATOS.
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20090087425A1 (en) 2007-08-10 2009-04-02 Topigen Pharmaceuticals Inc. Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease
RU2404792C1 (ru) * 2009-05-20 2010-11-27 Общество с ограниченной ответственностью Научно-производственное предприятие "БИОНОКС" Средство для преодоления стероидной резистентности
BR112013020498A2 (pt) * 2011-02-10 2016-08-09 Genqual Corp método para determinar a capacidade de resposta a inibidores e para tratamento de um sujeito
JP2014511181A (ja) 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
EP3722290B1 (en) * 2013-04-12 2023-06-21 VALENTA-INTELLEKT Limited Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative
RU2552929C1 (ru) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
GEAP202115467A (en) * 2017-09-07 2021-10-11 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines

Also Published As

Publication number Publication date
MD4851C1 (ro) 2023-11-30
KR20220162821A (ko) 2022-12-08
EP4218758A2 (en) 2023-08-02
PH12021551152A1 (en) 2021-10-25
RU2712281C1 (ru) 2020-01-28
JP2022508167A (ja) 2022-01-19
JP7518997B2 (ja) 2024-07-19
MX2022013503A (es) 2022-11-16
GEP20237467B (en) 2023-02-10
EA201992646A1 (ru) 2020-05-31
KR20210095652A (ko) 2021-08-02
ZA202210444B (en) 2023-01-25
MD20210032A2 (ro) 2021-09-30
GEAP202415619A (en) 2024-03-11
EP3884945A1 (en) 2021-09-29
CL2022000683A1 (es) 2022-10-28
IL297533A (en) 2022-12-01
BR112021009801A2 (pt) 2022-03-03
IL283317A (en) 2021-07-29
JP2023015333A (ja) 2023-01-31
GEAP202215712A (en) 2022-10-10
GEP20247643B (en) 2024-07-10
MD20210050A2 (ro) 2021-12-31
MY209416A (en) 2025-07-08
ZA202104247B (en) 2023-03-29
AU2022256212B2 (en) 2024-08-15
AU2019384626A1 (en) 2021-07-15
AU2022256212A1 (en) 2022-12-08
CL2021001316A1 (es) 2021-10-29
MD4851B1 (ro) 2023-04-30
CN113164464A (zh) 2021-07-23
EP4218758A3 (en) 2023-08-23
CN114652721A (zh) 2022-06-24
MD4844B1 (ro) 2023-02-28
MD4844C1 (ro) 2023-09-30
WO2020106191A1 (ru) 2020-05-28
US20220362230A1 (en) 2022-11-17
EP3884945A4 (en) 2022-11-23
CA3120882A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
MX2024015479A (es) Moduladores de la via de respuesta integrada al estres
PH12021550310A1 (en) Novel sulfonamideurea compounds
MX2020002652A (es) Esteroides neuroactivos y su método de uso.
GB201907616D0 (en) Novel compounds and pharmaceutical compositons thereof for the treatment of diseases
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2021004431A (es) Procesos novedosos.
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MX2024014845A (es) Esteroides neuroactivos no saturados 9(11) y sus metodos de uso
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
NZ759295A (en) 5-5 fused rings as c5a inhibitors
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2022009243A (es) Moduladores de la via de respuesta integrada al estres.
PH12021551152A1 (en) Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
BR112022007489A2 (pt) Forma amorfa de um receptor c5a de componente do complemento
PH12020500461A1 (en) 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-methylpropan-2-ol derivatives and related compounds as il-17 and ifn-gamma inhibitors for treating autoimmune diseases and chronic inflammation
PH12021550258A1 (en) Cdk8/19 inhibitors
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
MX2023007476A (es) Derivado de tetrahidroquinolina y uso medico del mismo.
SG10201907026RA (en) Prevention or Treatment of Uratic or Gouty Diseases
RU2014147728A (ru) Производное транс-2-деценовой кислоты и содержащее его лекарственное средство
MX2021014941A (es) Inhibidores de dopamina-b-hidroxilasa.
TH2101001964A (th) สารประกอบอินโดลิโนนสำหรับใช้เป็นสารยับยั้งmap4k1
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.
NZ762437A (en) Novel heterocyclic compounds as cdk8/19 inhibitors